D.E. Shaw & Co
NAMS icon

D.E. Shaw & Co’s NewAmsterdam Pharma NAMS Stock Holding History

D.E. Shaw & Co’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,345
Closed -$305K – 4710
2024
Q3 		$305K Buy
+18,345
New +$317K ﹤0.01% 3968

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

D.E. Shaw & Co's NAMS Position: Q4 2024 in Review

D.E. Shaw & Co sold out of NewAmsterdam Pharma (NAMS) in Q4 2024, closing a stake of 18,345 shares — an estimated $305K sold.

D.E. Shaw & Co first reported a position in NAMS in Q3 2024 and held it in 1 quarter. The position peaked at $305K in Q3 2024. 130 funds tracked by Wall St. Rank hold NAMS as of Q4 2024.

  • D.E. Shaw & Co reported no remaining NewAmsterdam Pharma position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 18,345 NewAmsterdam Pharma shares in Q4 2024, an estimated $305K.
  • D.E. Shaw & Co first reported a position in NewAmsterdam Pharma in Q3 2024 and held it in 1 quarter.
  • D.E. Shaw & Co's NewAmsterdam Pharma position peaked at $305K in Q3 2024.
  • 130 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.